Download PDF
Z Gastroenterol 2024; 62(09): 1644-1645
DOI: 10.1055/a-2373-7928
Mitteilungen der DGVS

Viszeralmedizin – Viszeralmedizin 2024 – 30. September – 05. Oktober 2024. Erst online. Dann vor Ort in Leipzig. DGVS Kongresspräsident 2024 – ein Porträt

› Further Information
Also available at
    Permissions and Reprints

Prof. Dr. med. Axel Dignaß

Zoom Image
Prof. Dr. med. Axel Dignaß

Korrespondenzadresse 
Prof. Dr. med. Britta Siegmund
Med. Klinik für Gastroenterologie, Infektiologie, Rheumatologie (einschl. Arbeitsbereich Ernährungsmedizin)
Charité – Universitätsmedizin Berlin
Hindenburgdamm 30
12 203 Berlin
britta.siegmund@charite.de



Publication History

Article published online:
09 September 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Dignass A, Lynch-Devaney K, Kindon H. et al. Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway. J Clin Invest 1994; 94: 376-383 DOI: 10.1172/JCI117332.
    CrossrefPubMedGoogle Scholar
  • 2 Dignass AU, Podolsky DK. Cytokine modulation of intestinal epithelial cell restitution: central role of transforming growth factor beta. Gastroenterology 1993; 105: 1323-1332 DOI: 10.1016/0016-5085(93)90136-z.
    CrossrefPubMedGoogle Scholar
  • 3 Dignass AU, Stow JL, Babyatsky MW. Acute epithelial injury in the rat small intestine in vivo is associated with expanded expression of transforming growth factor alpha and beta. Gut 1996; 38: 687-693 DOI: 10.1136/gut.38.5.687.
    CrossrefPubMedGoogle Scholar
  • 4 Turner D, Ricciuto A, Lewis A. et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 2021; 160: 1570-1583 DOI: 10.1053/j.gastro.2020.12.031.
    CrossrefPubMedGoogle Scholar